RedHill Biopharma reports positive preliminary results from ondansetron study
The study has met its objective of establishing bioequivalence to Zofran, the current approved reference listed drug. RedHill expects to file an application with the FDA for US
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.